Abstract
BackgroundAcute myeloid leukemia (AML) is a typically fatal malignancy and new drug and treatment need to be developed for a better survival outcome. Cold atmospheric plasma (CAP) is a novel technology, which has been widely applied in biomedicine, especially in various of cancer treatment. However, the changes in cell metabolism after CAP treatment of leukemia cells have been rarely studied.MethodsIn this study, we investigated the metabolite profiling of plasma treatment on leukemia cells based on Gas Chromatography Tandem Time-of-Flight Mass Spectrometry (GC-TOFMS). Simultaneously, we conducted a series of bioinformatics analysis of metabolites and metabolic pathways with significant differences after basic data analysis.Results800 signals were detected by GC–TOF mass-spectrometry and then evaluated using PCA and OPLS-DA. All the differential metabolites were listed and the related metabolic pathways were analyzed by KEGG pathway. The results showed that alanine, aspartate and glutamate metabolism had a significant change after plasma treatment. Meanwhile, d-glutamine and d-glutamate metabolism were significantly changed by CAP. Glutaminase activity was decreased after plasma treatment, which might lead to glutamine accumulation and leukemia cells death.ConclusionsWe found the above two metabolic pathways vulnerable to plasma treatment, which might result in leukemia cells death and might be the cornerstone of further exploration of plasma treatment targets.
Highlights
Acute myeloid leukemia (AML) is a typically fatal malignancy and new drug and treatment need to be developed for a better survival outcome
Inhibition of GLS after plasma treatment leading to disruption of glutamine metabolism We found that glutamine in alanine, aspartate and glutamate metabolism pathway and in d-glutamine and d-glutamate metabolism pathway was up-regulated in plasma treatment group (Fig. 5)
We investigated the changes in cell metabolism after Cold atmospheric plasma (CAP) treatment of leukemia cells by gas-chromatography time-of-flight (GC–TOF)–MS analysis
Summary
Acute myeloid leukemia (AML) is a typically fatal malignancy and new drug and treatment need to be developed for a better survival outcome. Cold atmospheric plasma (CAP) is a new technology that has attracted much attention in recent years especially in biomedical applications, such as bacterial disinfection, application of skin diseases, dentistry, cell transfection, wound healing and cancer treatment [3,4,5,6,7,8]. It is an ionized gas generated by electrical discharges in the atmospheric pressure at room temperature [9]. Cancer cells are able to achieve rapid and explosive proliferation due to metabolic
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
